Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

Wednesday, October 5, 2016 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., w

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.
Details of the presentation are as follows:
Jefferies Gene Editing/Therapy Summit
Date: Tuesday, October 11, 2016
Location: New York, New York
Times: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.
About Intellia Therapeutics
ShareAdd on Google
Tags: NTLA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 5, 2016

Biotech snapshot

Cash runway
$628M liquidity · $28M/mo burn
~22 mo
Low dilution risk
Lead asset
NTLA-2002Phase 3
Hereditary Angioedema →

Catalyst track record

+76%
best trade around NTLA's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for NTLA.

See every catalyst's timing & PoA →